This work highlights our significant efforts in transition of multi-omics single shot technology (MOST) to the nano-flow regime to improve the sensitive of the analysis. This project demonstrates the robustness of the nMOST platform with minimal change in biomolecule quantification across >350 analyses. To further develop the MOST platform we have been exploring chromatographic conditions that would enable the addition of metabolites.
Global cellular proteo-lipidomic profiling of diverse lysosomal storage disease mutants using nMOST.